Unlike A20, the inactivation of CYLD is found in blood cancers, including leukemia [13], and a downregulated expression of Cezanne is reported in solid cancers, such as hepatocellular carcinoma [16]. This evidence concerns the gene TNFAIP3 and hematopoietic and lymphoid system neoplasm.